HYDIA

HYDIA
(IUPAC) ime
	(1S,2R,3R,5R,6S)-2-amino-3-hidroksibiciklo[3.1.0]heksan-2,6-dikarboksilna kiselina
Klinički podaci
Identifikatori
ATC kod	nije dodeljen
PubChem	9794223
Hemijski podaci
Formula	C8H11NO5
Mol. masa	201,176 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C8H11NO5/c9-8(7(13)14)3(10)1-2-4(5(2)8)6(11)12/h2-5,10H,1,9H2,(H,11,12)(H,13,14)/t2-,3+,4-,5-,8-/m0/s1 ; Key: NTPXNEQCDPWJQA-AZDHXYLBSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

HYDIA je lek koji se koristi u neurološkim istraživanjima. On deluje kao potentan i selektivan antagonist grupe II metabotropnih glutamatnih receptora (mGluR_2/3). On je bio koristan u mapiranju proteina grupe II mGluR receptora i njihovom molekulskom modelovanju.^[3] HYDIA ima sličnu strukturu sa agonistima grupe II mGluR kao što su eglumegad i LY-404,039, ali dodatak 3-hidroksi grupe menja njegovo dejstvo u kompetitivni antagonist. Drugi derivati kao što je 3-benziloksi etar su potentniji antagonisti od samog HYDIA.^[4]

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Lundström L, Kuhn B, Beck J, Borroni E, Wettstein JG, Woltering TJ, Gatti S (July 2009). „Mutagenesis and molecular modeling of the orthosteric binding site of the mGlu2 receptor determining interactions of the group II receptor antagonist (3)H-HYDIA”. Chemmedchem 4 (7): 1086–94. DOI:10.1002/cmdc.200900028. PMID 19402024.
↑ Woltering TJ, Adam G, Huguenin P, Wichmann J, Kolczewski S, Gatti S, Bourson A, Kew JN, Richards G, Kemp JA, Mutel V, Knoflach F (February 2008). „Asymmetric synthesis and receptor pharmacology of the group II mGlu receptor ligand (1S,2R,3R,5R,6S)-2-amino-3-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid-HYDIA”. Chemmedchem 3 (2): 323–35. DOI:10.1002/cmdc.200700226. PMID 18058780.

Spoljašnje veze uredi

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[pmid19402024-3] Lundström L, Kuhn B, Beck J, Borroni E, Wettstein JG, Woltering TJ, Gatti S (July 2009). „Mutagenesis and molecular modeling of the orthosteric binding site of the mGlu2 receptor determining interactions of the group II receptor antagonist (3)H-HYDIA”. Chemmedchem 4 (7): 1086–94. DOI:10.1002/cmdc.200900028. PMID 19402024.

[pmid18058780-4] Woltering TJ, Adam G, Huguenin P, Wichmann J, Kolczewski S, Gatti S, Bourson A, Kew JN, Richards G, Kemp JA, Mutel V, Knoflach F (February 2008). „Asymmetric synthesis and receptor pharmacology of the group II mGlu receptor ligand (1S,2R,3R,5R,6S)-2-amino-3-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic acid-HYDIA”. Chemmedchem 3 (2): 323–35. DOI:10.1002/cmdc.200700226. PMID 18058780.

[3]

[4]

[1]

[2]